Semaglutide
Ozempic · Wegovy · Rybelsus
A once-weekly injectable (or daily oral) GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. FDA-approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction — the most-studied peptide drug on the modern market.
What is it?
Semaglutide is a synthetic GLP-1 receptor agonist developed by Novo Nordisk and marketed under three brand names: Ozempic (subcutaneous, type 2 diabetes, approved 2017), Wegovy (subcutaneous, chronic weight management, approved 2021), and Rybelsus (oral, type 2 diabetes, approved 2019). It shares 94% sequence homology with native human GLP-1 but is engineered with two key modifications — an α-aminoisobutyric acid (Aib) substitution at position 8 to resist DPP-4 degradation, and a C18 fatty diacid side chain at Lys26 to enable albumin binding. Together these extend the half-life from roughly 2 minutes (native GLP-1) to approximately 7 days.
The STEP trial program established semaglutide 2.4 mg weekly as a clinical standard for chronic weight management, producing mean weight loss of approximately 15% at 68 weeks in non-diabetic adults with obesity. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity — the first GLP-1 agonist to earn a cardiovascular indication in patients without diabetes.
Mechanism of Action
Semaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed in the pancreas, gastrointestinal tract, and central nervous system. Its therapeutic effects arise from four principal actions:
Arrows run from molecule to outcome. The brain-access step is from rodents; the eating and weight steps were measured in people.
Each step is tagged with where it was shown. A dashed red arrow marks a link the evidence does not establish.
The pathway in words
- Semaglutide. GLP-1 with two amino-acid changes and a fatty-acid chain that binds albumin and resists breakdown, designed for once-weekly dosing. Shown in: lab, animals. Source: PubMed 26308095.
- GLP-1 receptors. Its effects run through GLP-1 receptors: pancreatic receptors account for the glucose lowering and brain receptors for the weight loss. Shown in: review. Source: PubMed 31031702.
- Reaching the brain. In rodents it reached the brainstem, septal nucleus and hypothalamus through circumventricular organs without crossing the blood-brain barrier, activating 10 brain areas. Shown in: animals. Source: PubMed 32213703.
- Eating less. In 30 people with obesity over 12 weeks, intake at free-choice meals fell 24%, with less hunger and craving and no change in resting metabolic rate. Shown in: people. Source: PubMed 28266779.
- Weight loss. In 1,961 adults over 68 weeks, weight fell 14.9% on 2.4 mg weekly against 2.4% on placebo. Shown in: people. Source: PubMed 33567185.
Glucose-Dependent Insulin Secretion
Semaglutide binding to pancreatic β-cell GLP-1 receptors enhances insulin secretion only when blood glucose is elevated. This glucose-dependence is why semaglutide carries a much lower hypoglycemia risk than insulin or sulfonylureas. Insulin response is amplified during and after meals, contributing to post-prandial glucose control.
Glucagon Suppression
GLP-1 receptor activation on pancreatic α-cells suppresses inappropriate glucagon release. In type 2 diabetes, α-cell dysfunction causes elevated fasting glucagon; semaglutide restores more appropriate glucagon regulation, reducing hepatic glucose output.
Gastric Emptying Delay
Semaglutide slows gastric emptying, prolonging satiety after meals and blunting post-prandial glucose spikes. This effect tends to attenuate over weeks of treatment but contributes meaningfully to early weight loss and the characteristic GI side-effect profile (nausea, fullness, reflux).
Central Appetite Suppression
The dominant weight-loss mechanism. Semaglutide crosses into circumventricular regions (area postrema, arcuate nucleus of the hypothalamus) where it activates POMC/CART neurons and inhibits NPY/AgRP neurons. The result is reduced hunger, increased satiety, and diminished reward-driven eating — patients typically report a quieting of 'food noise'.
Cardiovascular & Inflammatory Effects
Beyond glucose and weight, semaglutide demonstrably reduces systemic inflammation, improves endothelial function, and lowers blood pressure modestly. The SELECT trial attributed cardiovascular benefit to a combination of weight loss, glycemic control, and direct vascular effects that are not fully explained by the primary metabolic endpoints.
Published Research
Semaglutide has one of the deepest human trial datasets of any peptide in history, with over 200 published clinical trials across three indication clusters (diabetes, obesity, cardiovascular). The list below highlights landmark and representative studies. Filter by study type below.
FLOW: Semaglutide in Chronic Kidney Disease
In patients with T2DM and CKD, semaglutide 1.0 mg weekly reduced the composite kidney-failure endpoint by 24% over 3.4 years. Trial stopped early for efficacy.
SELECT: Cardiovascular Outcomes in Obesity without Diabetes
In 17,604 adults with prior CV disease and BMI ≥27, semaglutide 2.4 mg weekly reduced MACE by 20% over 3.3 years. First GLP-1 agonist to show CV benefit in non-diabetic obesity.
GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications
Review of how GLP-1 receptor agonists produce weight loss — central appetite signalling, delayed gastric emptying and energy-intake effects — and what that means for clinical use.
STEP TEENS: Semaglutide in Adolescents with Obesity
Once-weekly semaglutide 2.4 mg produced a mean BMI reduction of 16.1% in adolescents aged 12–17, compared with 0.6% gain in placebo. Supported FDA approval of Wegovy for this age group.
STEP 5: 2-Year Weight Management Trial
Semaglutide 2.4 mg maintained a mean weight loss of 15.2% at 104 weeks, compared with 2.6% on placebo. Demonstrates durability beyond the 68-week STEP 1 endpoint.
STEP 8: Semaglutide vs Liraglutide Head-to-Head
Semaglutide 2.4 mg weekly produced 15.8% weight loss vs 6.4% for liraglutide 3.0 mg daily over 68 weeks, establishing semaglutide as the superior GLP-1 for weight management.
STEP 1: Once-Weekly Semaglutide in Obesity
Landmark obesity trial. 1,961 adults without diabetes, BMI ≥30 (or ≥27 with comorbidity). Mean weight loss of 14.9% at 68 weeks vs 2.4% placebo. Basis for Wegovy FDA approval.
PIONEER 6: Oral Semaglutide Cardiovascular Safety
Oral semaglutide (Rybelsus) demonstrated non-inferiority to placebo for MACE in T2DM, with a trend toward benefit. Supported 2019 FDA approval of the oral formulation.
Dosing Data
Semaglutide is prescription-only. The rows below are the current US labels for Ozempic, Wegovy and Rybelsus, injections and tablets, as DailyMed published them on September 30, 2026. The prescriber sets the dose for the indication, the response and how it is tolerated.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
→ Full Semaglutide dosage guide — the Wegovy and Ozempic escalation steps and the oral schedules.
→ Blend & Stack Calculator — Semaglutide is also sold in multi-peptide vials; the calculator shows what each draw delivers of every component; our blends and stacks hub sets out what each mix contains and what has been studied.
Side Effects & Contraindications
Reported Side Effects
Based on large Phase III trials (STEP, SUSTAIN, PIONEER) and post-marketing surveillance. GI side effects are the most common cause of discontinuation and are largely titration-dependent:
Contraindications & Cautions
Based on FDA prescribing information. Absolute and relative contraindications:
Legal Status
Semaglutide is a prescription medication approved in every major market. Compounded versions have been a regulatory flashpoint in the US due to persistent brand-name supply shortages — as of April 2026, both Ozempic and Wegovy are off the FDA shortage list, meaning large-scale compounding is no longer permitted.
Frequently Asked Questions
?What is semaglutide used for?
Semaglutide is FDA-approved for three indications: type 2 diabetes mellitus (as Ozempic, subcutaneous, or Rybelsus, oral), chronic weight management in adults and adolescents aged 12+ (as Wegovy, subcutaneous), and reduction of major adverse cardiovascular events in adults with overweight or obesity plus established cardiovascular disease (as Wegovy). It is not approved for cosmetic or non-medical weight loss.
?How much weight can you lose on semaglutide?
In the STEP 1 trial, adults without diabetes on Wegovy 2.4 mg weekly lost an average of 14.9% of body weight at 68 weeks, compared with 2.4% on placebo. About one-third of participants lost ≥20%. Weight loss plateaus around 65–70 weeks and is maintained with continued treatment; discontinuation typically leads to substantial regain.
?What is the difference between Ozempic and Wegovy?
Same active molecule (semaglutide), different branding, dosing, and FDA indications. Ozempic is approved for type 2 diabetes at doses of 0.25–2.0 mg weekly. Wegovy is approved for chronic weight management at doses of 0.25–2.4 mg weekly. Rybelsus is the oral tablet form (3–14 mg daily) for type 2 diabetes only. Insurance coverage differs substantially across the three.
?Semaglutide vs tirzepatide — which is better?
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist and has produced higher weight loss in head-to-head comparison. In SURMOUNT-5 (NEJM 2025), tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide at 72 weeks — a 47% greater relative reduction. Tirzepatide is generally considered more potent for weight loss; semaglutide has the larger cardiovascular outcomes dataset (SELECT trial). See our dedicated comparison article for a detailed breakdown.
?What are the side effects of semaglutide?
The most common side effects are gastrointestinal: nausea (up to 44% during titration), diarrhea or constipation, vomiting, and abdominal discomfort. These are largely dose-dependent and improve with slower titration. Rare but serious risks include pancreatitis, gallbladder disease, worsening of diabetic retinopathy with rapid glycemic improvement, and a boxed warning for medullary thyroid carcinoma based on rodent data.
?How long do you have to take semaglutide?
Indefinitely, if the indication persists. Semaglutide is a chronic therapy for chronic conditions — both diabetes and obesity are relapsing-remitting. Discontinuation studies consistently show that the majority of lost weight returns within a year. The STEP 4 trial demonstrated that stopping semaglutide at week 20 led to regaining about two-thirds of lost weight by week 68.
?Can I get semaglutide from a compounding pharmacy?
As of April 2026, large-scale compounding of semaglutide is not FDA-permitted. The FDA removed both Ozempic and Wegovy from the drug shortage list in early 2025, which ended the regulatory pathway that had allowed compounded versions during the 2022–2024 supply crisis. 503A patient-specific compounding remains possible under narrow circumstances, but mass-produced 'semaglutide from a compounder' is no longer lawful.
?Does semaglutide cause muscle loss?
All weight loss — pharmacologic or behavioral — includes some lean-mass component. Analyses of STEP trial body composition data suggest approximately 25–40% of total weight loss on semaglutide is lean mass, similar to the proportion seen in dietary weight loss. Resistance training and adequate protein intake (≥1.2 g/kg/day) substantially mitigate this effect.
?Can you drink alcohol on semaglutide?
No absolute contraindication, but two cautions apply. First, semaglutide slows gastric emptying, which can prolong and intensify alcohol's effects. Second, emerging observational data suggest GLP-1 agonists reduce craving for alcohol — some patients report spontaneously reducing intake. Heavy drinking also increases pancreatitis risk, which is already a concern with GLP-1 therapy.
?What happens if you stop semaglutide suddenly?
No withdrawal syndrome or acute dangers from stopping semaglutide. However, the therapeutic effects end when the drug clears — which takes approximately 5 weeks at full elimination due to the 7-day half-life. Appetite returns, and weight regain typically begins within weeks. For type 2 diabetes, glucose control deteriorates back toward pre-treatment baseline. Sudden discontinuation is not medically dangerous but rarely clinically advised.
References
- [fda-pi] Ozempic (semaglutide) Prescribing Information. Novo Nordisk.
- [fda-pi] Wegovy (semaglutide) Prescribing Information. Novo Nordisk.
- [clinical-trial] Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." N Engl J Med, 2021;384:989-1002. PMID: 33567185.
- [clinical-trial] Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." N Engl J Med, 2023;389:2221-2232. PMID: 37952131.
- [pubmed] Perkovic V, et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." N Engl J Med, 2024;391(2):109-121. PMID: 38785209.
- [pubmed] Moore PW, et al. "GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications." Adv Ther, 2023;40(3):723-742. PMID: 36566341.
- [pubmed] Weghuber D, et al. "Once-Weekly Semaglutide in Adolescents with Obesity." N Engl J Med, 2022;387(24):2245-2257. PMID: 36322838.
- [pubmed] Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nat Med, 2022;28(10):2083-2091. PMID: 36216945.
- [pubmed] Rubino DM, et al. "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial." JAMA, 2022;327(2):138-150. PMID: 35015037.
- [pubmed] Husain M, et al. "Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med, 2019;381(9):841-851. PMID: 31185157.
- [pubmed] Lau J, et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." J Med Chem, 2015;58(18):7370-80. PMID: 26308095.
- [pubmed] Knudsen LB, et al. "The Discovery and Development of Liraglutide and Semaglutide." Front Endocrinol (Lausanne), 2019;10:155. PMID: 31031702.
- [pubmed] Gabery S, et al. "Semaglutide lowers body weight in rodents via distributed neural pathways." JCI Insight, 2020;5(6). PMID: 32213703.
- [pubmed] Blundell J, et al. "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity." Diabetes Obes Metab, 2017;19(9):1242-1251. PMID: 28266779.
- [fda] US FDA, Drug Shortages database (openFDA drug/shortages, status 'To Be Discontinued'): Rybelsus (semaglutide) tablets 3, 7 and 14 mg, 'to be replaced by Ozempic (semaglutide) tablets', posted June 4, 2026. Read October 5, 2026.
Sources & Citations
Molecular data from FDA prescribing information and PubChem. Clinical trial data from the STEP, SUSTAIN, PIONEER, and SELECT programs as published in peer-reviewed journals (NEJM, Lancet, JAMA). Legal status information current as of April 2026. Dosing protocols reflect current FDA-approved labeling for Ozempic, Wegovy, and Rybelsus. This page is reviewed and updated monthly. It is educational content and does not constitute medical advice.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.